Q32 Bio Inc. — Director's Dealing 2023

Jun 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-06-14

Reporting Person: GILLIS STEVEN (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-14	Option (Right to Buy)	$1.03	A	23000	Acquired	2023-06-14	Common Stock (23000)	Direct

Footnotes

F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.